TD Cowen raised the firm’s price target on Elevance Health (ELV) to $380 from $330 and keeps a Buy rating on the shares. The firm noted the company maintained FY25 guide but FY26 implied lower versus consensus on a more negative MDCD outlook, offset by more upbeat MA expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health: Strategic Outlook and EPS Growth Support Buy Rating
- Elevance Health price target lowered to $385 from $395 at Barclays
- Elevance Health Reports Strong Q3 2025 Revenue Growth
- Morning Movers: General Motors and RTX higher following Q3 reports
- Elevance Health reports Q3 adjusted EPS $6.03, consensus $4.94